IL163719A0 - Use of substituted phenyl-5-alkoxy-1,3,4-oxdiazol-2-ones for producing medicaments with an inhibitory effect on pancreatic lipase - Google Patents

Use of substituted phenyl-5-alkoxy-1,3,4-oxdiazol-2-ones for producing medicaments with an inhibitory effect on pancreatic lipase

Info

Publication number
IL163719A0
IL163719A0 IL16371903A IL16371903A IL163719A0 IL 163719 A0 IL163719 A0 IL 163719A0 IL 16371903 A IL16371903 A IL 16371903A IL 16371903 A IL16371903 A IL 16371903A IL 163719 A0 IL163719 A0 IL 163719A0
Authority
IL
Israel
Prior art keywords
oxdiazol
alkoxy
ones
substituted phenyl
inhibitory effect
Prior art date
Application number
IL16371903A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of IL163719A0 publication Critical patent/IL163719A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16371903A 2002-02-28 2003-02-17 Use of substituted phenyl-5-alkoxy-1,3,4-oxdiazol-2-ones for producing medicaments with an inhibitory effect on pancreatic lipase IL163719A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10208986A DE10208986A1 (de) 2002-02-28 2002-02-28 Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase
PCT/EP2003/001560 WO2003072098A1 (de) 2002-02-28 2003-02-17 Verwendung substituierter 3-phenyl-5-alkoxy-1,3,4-oxdiazol-2-one zur herstellung von arzneimitteln mit hemmender wirkung an der pankreatischen lipase

Publications (1)

Publication Number Publication Date
IL163719A0 true IL163719A0 (en) 2005-12-18

Family

ID=27740557

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16371903A IL163719A0 (en) 2002-02-28 2003-02-17 Use of substituted phenyl-5-alkoxy-1,3,4-oxdiazol-2-ones for producing medicaments with an inhibitory effect on pancreatic lipase

Country Status (20)

Country Link
EP (1) EP1482929A1 (pl)
JP (1) JP2005519079A (pl)
KR (1) KR20040101250A (pl)
CN (1) CN1638766A (pl)
AR (1) AR038702A1 (pl)
AU (1) AU2003210292A1 (pl)
BR (1) BR0308045A (pl)
CA (1) CA2477005A1 (pl)
CO (1) CO5611144A2 (pl)
DE (1) DE10208986A1 (pl)
HR (1) HRP20040783A2 (pl)
HU (1) HUP0500093A2 (pl)
IL (1) IL163719A0 (pl)
MA (1) MA27173A1 (pl)
MX (1) MXPA04007480A (pl)
NO (1) NO20044091L (pl)
PL (1) PL371310A1 (pl)
RU (1) RU2004128932A (pl)
TW (1) TW200400026A (pl)
WO (1) WO2003072098A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5080970B2 (ja) 2004-06-17 2012-11-21 サイトキネティクス・インコーポレーテッド 心疾患を治療するための置換尿素誘導体
AU2005298692A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
EP1962852B1 (en) 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
CA2708447C (en) * 2007-12-25 2016-05-10 Kissei Pharmaceutical Co., Ltd. Novel catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition
AR074978A1 (es) 2008-12-23 2011-03-02 Bial Portela & Ca Sa 3-n-aril-1,3,4-oxadiazolonas 5-o-sustituidas para uso en el tratamiento del dolor y procedimiento de obtencion
CN103086859B (zh) * 2011-11-08 2015-11-11 清华大学 2,4-二羟基-5,6-取代-1-卤代苯衍生物、其合成方法及其应用
CN111527065B (zh) * 2017-09-01 2024-05-07 科廷大学 油酰基-溶血磷脂酰肌醇(油酰基-lpi)的合成衍生物及其用途
CN109879839B (zh) * 2019-03-12 2023-04-25 沈阳大学 6-哌嗪甲基-7-羟基苯并呋喃类化合物及其医药用途
PH12022552021A1 (en) * 2020-02-07 2024-02-05 Cytokinetics Inc Nampt modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19942354A1 (de) * 1999-09-04 2001-03-08 Aventis Pharma Gmbh Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneimitteln
RU2281283C2 (ru) * 2000-03-07 2006-08-10 Санофи-Авентис Дойчланд Гмбх Замещенные 3-фенил-5-алкокси-1,3,4-оксадиазол-2-оны и их применение для ингибирования гормоночувствительной липазы

Also Published As

Publication number Publication date
CO5611144A2 (es) 2006-02-28
NO20044091L (no) 2004-09-27
BR0308045A (pt) 2004-12-21
EP1482929A1 (de) 2004-12-08
CA2477005A1 (en) 2003-09-04
HUP0500093A2 (hu) 2005-04-28
RU2004128932A (ru) 2005-04-10
AU2003210292A1 (en) 2003-09-09
WO2003072098A1 (de) 2003-09-04
CN1638766A (zh) 2005-07-13
PL371310A1 (pl) 2005-06-13
DE10208986A1 (de) 2003-09-11
TW200400026A (en) 2004-01-01
AR038702A1 (es) 2005-01-26
HRP20040783A2 (en) 2005-04-30
MA27173A1 (fr) 2005-01-03
JP2005519079A (ja) 2005-06-30
MXPA04007480A (es) 2004-11-10
KR20040101250A (ko) 2004-12-02

Similar Documents

Publication Publication Date Title
ZA200500086B (en) Novel carboxamide compounds having an MCH-antagonistic effect, medicaments containing said compounds, and method for the production thereof
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
EG25011A (en) Amino-piperidin-1-yl-xanthines, the production thereof and the use of the same as medicaments.
ZA200302553B (en) Arrangement of radial bogie.
AU2003282094A1 (en) Novel dihydroxy-methylphenyl derivatives, method for the production and use thereof as medicaments
AU2003257465A1 (en) Substituted diaryl heterocycles, method for the production and use thereof as medicaments
AU2003295890A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
AU2003288023A1 (en) Process for the manufacture of 1,2-epoxy-3-chloropropane
IL165973A0 (en) Method for the treatment of multiple sclerosis
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
IL163719A0 (en) Use of substituted phenyl-5-alkoxy-1,3,4-oxdiazol-2-ones for producing medicaments with an inhibitory effect on pancreatic lipase
WO2003063796A3 (en) Heterocyclic arylsulfonamidobenzylic compounds
AU2003298913A1 (en) Treatment of inflammatory disorders with 2,3-benzodiazepines
AU2003224002A1 (en) Drugs for the arthritis treatment
WO2003079962A3 (de) Zusammenhängende einheit aus vereinzelbaren transdermalen therapeutischen systemen
AU2003233820A1 (en) Method for the treatment of starch
AU2002353510A1 (en) Nebuliser
AU2003201163A1 (en) Method for the preparation of lariciresinol, cyclolariciresinol and secoisolariciresinol
AU2003210287A1 (en) Coolant distributor
AU2003292209A1 (en) Method for the production of optically active dihydropyrones
AU2003209534A1 (en) The method of treating tuberculosis
AU2003267541A1 (en) Method for the production of substituted trifluoroethylenes
AU2003218718A1 (en) Utilization of ubiquinones for influencing the effect of histamine
AU2003259689A1 (en) 3-imino-2-indolones for the treatment of depression and/or anxiety
NO20041295L (no) Tieno(1,3)oksazin-4-oner med lipaseinhiberende aktivitet